X4 Pharmaceuticals

XFORNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$437.643 M

$4.64 +11.27%

Close of 7 Aug 2026

Revenue

$6.50M

#3255 by revenue

Earnings

-$79.2M

Loss-making

Shares outstanding

99,146,743

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#72Cabaletta BioCABA$454.9M
#73Editas MedicineEDIT$442.3M
#74X4 PharmaceuticalsXFOR$437.6M
#75OcugenOCGN$434.1M
#76Scribe TherapeuticsSCTX$420.7M

Where these numbers come from

Share counts and financials for X4 Pharmaceuticals are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.